Inmed pharmaceuticals reports full year fiscal 2024 financial results and provides business update

Advances inm-901 program targeting several biological pathways associated with alzheimer's disease further develops inm-089 demonstrating neuroprotection in the treatment of dry age-related macular degeneration $4.6m revenues in fiscal year 2024, representing a 11% increase over the previous fiscal year vancouver, british columbia--(newsfile corp. - september 30, 2024) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed" or the "company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced financial results for the fiscal year ending june 30, 2024 and provided a business update on the pharmaceutical drug development programs as well as the commercial segment for its wholly-owned subsidiary, baymedica, llc ("baymedica"). the company's full financial statements and related md&a for the fiscal year ended june 30, 2024, are available at www.inmedpharma.com and at www.sedar.com.
INM Ratings Summary
INM Quant Ranking